Dissolution and disintegration are the only tests for solid oral dosage forms that are 'predictive' of in vivo release rates. Historically, these tests have been described in the pharmacopoeias, but they struggle to show in vivo predictivity, whilst maintaining the robustness demanded by any routine QC tool.
This symposium will look at the role of these tests and what the future holds.
This symposium will look at the role of these tests and what the future holds.
